Get the Stockscreener App
0.8063
2.09%
-0.0163
Adial Pharmaceuticals Inc stock is traded at $0.8063, with a volume of 10,994.
It is down -2.09% in the last 24 hours and down -27.71% over the past month.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
See More
Previous Close:
$0.79
Open:
$0.775
24h Volume:
10,994
Relative Volume:
0.06
Market Cap:
$5.11M
Revenue:
-
Net Income/Loss:
$-6.07M
P/E Ratio:
-0.1395
EPS:
-5.78
Net Cash Flow:
$-7.34M
1W Performance:
-6.81%
1M Performance:
-27.71%
6M Performance:
-21.96%
1Y Performance:
-36.59%
1-Day Range:
$0.771
$0.8064
1-Week Range:
$0.7622
$0.84
52-Week Range:
$0.7151
$4.1699
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Name
Adial Pharmaceuticals Inc
Sector
Industry
Phone
434-422-9800
Address
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
0.8063 | 5.11M | 0 | -6.07M | -7.34M | -5.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.30 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.97 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-18 | Initiated | Maxim Group | Buy |
| Oct-11-18 | Initiated | Dawson James | Buy |
Adial Pharmaceuticals Inc Stock (ADIL) Latest News
Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries - ACCESS Newswire
Clinical Trials News Live Feed - StockTitan
Adial completes key study for alcohol disorder drug - MSN
Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder - ACCESS Newswire
ADILAdial Pharmaceuticals, Inc Latest Stock News & Market Updates - StockTitan
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - The Manila Times
Game-Changing Alcohol Addiction Treatment Clears Critical FDA Hurdle - StockTitan
EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder - Benzinga
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 60.8% in January - Defense World
Adial Pharma stock hits 52-week low at $0.72 amid market challenges - Investing.com Nigeria
Adial Pharmaceuticals Announces Appointment of Alex Lugovoy as Head of Strategy - ACCESS Newswire
Why Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars Today - MSN
Adial Pharmaceuticals to Commence Business Development Meetings - Defense World
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
Adial Pharmaceuticals Focuses on Strategic Growth Initiatives - TipRanks
Adial Pharmaceuticals Highlights AD04 for Alcohol Use Disorder - TipRanks
Alcohol Use Disorder Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight - Barchart
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Up 16.4% in December - Defense World
Adial Pharmaceuticals (NASDAQ:ADIL) Stock Quotes, Forecast and News Summary - Benzinga
Adial Pharmaceuticals’ New Purchase Agreement with Alumni Capital - TipRanks
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Drops By 71.7% - Defense World
Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Adial Pharmaceuticals revises CEO's compensation package By Investing.com - Investing.com South Africa
Adial Pharmaceuticals revises CEO's compensation package - Investing.com India
Adial Pharmaceuticals secures new patent for AUD therapy By Investing.com - Investing.com South Africa
EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations - AOL
Adial Pharmaceuticals, Inc. Updates on Onward Phase 3 Pivotal Trial - Marketscreener.com
Adial Pharmaceuticals secures new patent for AUD therapy - Investing.com
Adial Pharmaceuticals Granted Key U.S. Patent for the - GlobeNewswire
Adial Pharmaceuticals Secures Key Patent for Alcohol Use Disorder Treatment Technology - StockTitan
Alcohol Use Disorder Treatment Market Report Analysis - openPR
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Large Growth in Short Interest - Defense World
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know - MSN
Equities Analysts Offer Predictions for ADIL FY2024 Earnings - Defense World
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Adial Pharmaceuticals (NASDAQ:ADIL) Coverage Initiated at Rodman & Renshaw - Defense World
RODMAN&RENSHAW Upgrades Adial Pharmaceuticals (NASDAQ:ADIL) to “Strong-Buy” - Defense World
ARMISTICE CAPITAL, LLC Acquires New Stake in Adial Pharmaceutica - GuruFocus.com
Rodman & Renshaw sets stock target, buy rating on Adial Pharma, cites potential - Investing.com India
U.S. STOCKS Oklo, Adial Pharma, Sonos - XM
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder - AOL
Adial Pharmaceuticals completes key study for FDA meeting - Investing.com
Adial Pharmaceuticals Inc Stock (ADIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):